# Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome

> **NCT03789175** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 1 (actual)

## Conditions studied

- Cancer
- Skin Fibroblasts
- Muscle Weakness

## Interventions

- **DIETARY_SUPPLEMENT:** Nicotinamide Riboside (NR)

## Key facts

- **NCT ID:** NCT03789175
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-25
- **Primary completion:** 2019-11-01
- **Final completion:** 2019-11-01
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03789175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03789175, "Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03789175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*